On October 28, 2021 ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported the presentation of preclinical data characterizing the mechanism of action of EPI-7386, ESSA’s lead product candidate for the treatment of prostate cancer (Press release, ESSA, OCT 28, 2021, View Source [SID1234592151]). Data were presented in a poster format at the 2021 Prostate Cancer Foundation (PCF) Scientific Retreat, taking place virtually October 28-29, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data include the results of nuclear magnetic resonance (NMR) studies which confirm the binding of the compound to the N-terminal domain (NTD) of the androgen receptor (AR), a region not currently targeted by other antiandrogen therapies. The data were recently presented at the 2021 AACR (Free AACR Whitepaper)-NCI-EORTC Virtual AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper).

Presentation details are as follows:

2021 Prostate Cancer Foundation (PCF) Scientific Retreat

Title: Comprehensive preclinical characterization of the mechanism of action of EPI-7386, an androgen receptor N-terminal domain inhibitor
Presenter: Dr. Nan Hyung Hong
Date: October 28, 2021

The poster is available on the 2021 PCF Retreat virtual meeting website and the "Publications" section of the Company’s website at www.essapharma.com.